Literature DB >> 21143353

Risk factors for relapse of visceral leishmaniasis in Georgia.

Maia Kajaia1, Dale L Morse, George Kamkamidze, Maia Butsashvili, Giulen Chubabria, Otar Zenaishvili, Nora Kokaia, Louise-Anne McNutt.   

Abstract

The number of relapses in patients treated for visceral leishmaniasis (VL) has increased, thus identifying prognostic factors may aid decisions on treatment. Demographic and clinical information was abstracted from medical records of patients diagnosed and treated in Georgia from 2002 to 2004. The 300 persons with VL were primarily children <5 years (73.3%), and ∼44% had delays in diagnosis of more than 30 days from symptom onset. All patients received standard therapy with pentavalent antimony (20 mg/kg/day), most for 20-25 days. Factors significantly associated with VL relapse were delay in diagnosis for >90 days (RR = 4.21, 95% CI: 1.58, 11.16), haemoglobin level <60 g/l (RR = 11.96, 95% CI: 4.12, 34.76) and age <1 year (RR = 2.36, 95% CI: 0.96, 5.80). Physician and public education is needed to reduce delays in diagnosis. Prolonging treatment for 30 days (e.g. WHO recommendation) or implementing new regimens may reduce the number of relapses.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21143353     DOI: 10.1111/j.1365-3156.2010.02694.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  7 in total

1.  Early clinical manifestations associated with death from visceral leishmaniasis.

Authors:  Valdelaine Etelvina Miranda de Araújo; Maria Helena Franco Morais; Ilka Afonso Reis; Ana Rabello; Mariângela Carneiro
Journal:  PLoS Negl Trop Dis       Date:  2012-02-07

2.  Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.

Authors:  Sakib Burza; Prabhat K Sinha; Raman Mahajan; María Angeles Lima; Gaurab Mitra; Neena Verma; Manica Balasegaram; Manica Balsegaram; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2014-01-02

3.  Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia.

Authors:  Getachew Mebrahtu Welay; Kefyalew Addis Alene; Berihun Assefa Dachew
Journal:  Epidemiol Health       Date:  2016-12-28

4.  Visceral Leishmaniasis Treatment Outcome and Associated Factors in Northern Ethiopia.

Authors:  Kidu Gidey; Desalegn Belay; Berhane Yohannes Hailu; Tesfaye Dessale Kassa; Yirga Legesse Niriayo
Journal:  Biomed Res Int       Date:  2019-08-21       Impact factor: 3.411

5.  The increasing incidence of visceral leishmaniasis relapse in South Sudan: A retrospective analysis of field patient data from 2001-2018.

Authors:  Gabriel Naylor-Leyland; Simon M Collin; Francis Gatluak; Margriet den Boer; Fabiana Alves; Abdul Wasay Mullahzada; Koert Ritmeijer
Journal:  PLoS Negl Trop Dis       Date:  2022-08-18

Review 6.  The current epidemiology of leishmaniasis in Turkey, Azerbaijan and Georgia and implications for disease emergence in European countries.

Authors:  Yusuf Özbel; Seray Töz; Clara Muñoz; Maria Ortuño; Zarima Jumakanova; Pedro Pérez-Cutillas; Carla Maia; Cláudia Conceição; Gad Baneth; André Pereira; Yves Van der Stede; Céline M Gossner; Eduardo Berriatua
Journal:  Zoonoses Public Health       Date:  2022-05-26       Impact factor: 2.954

7.  Cost-effectiveness of diagnostic-therapeutic strategies for paediatric visceral leishmaniasis in Morocco.

Authors:  Sergi Alonso; Nabil Tachfouti; Adil Najdi; Elisa Sicuri; Albert Picado
Journal:  BMJ Glob Health       Date:  2017-08-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.